Introduction

Knee osteoarthritis is a common and often challenging condition that affects many people across the UK, especially as they get older. It causes pain, stiffness, and limited movement, which can make everyday activities difficult and impact quality of life. Finding effective treatments that can ease symptoms and delay the need for surgery remains a priority for both patients and healthcare professionals.

One promising option that has attracted attention is Arthrosamid injection — a non-surgical treatment designed to relieve knee osteoarthritis symptoms. However, despite its potential, Arthrosamid is not yet widely available on the NHS, leaving many patients wondering why and what alternatives they have.

This article unpacks the reasons behind the limited NHS availability of Arthrosamid injections, explores what this means for patients, and highlights how leading experts like Professor Paul Lee and the team at MSK Doctors are helping patients navigate their options with informed advice and personalised care. The concept of “arthrosamid nhs availability” will be our focus, offering clarity around access, evidence, and what the future might hold.

What Is Arthrosamid and How Does It Help Knee Osteoarthritis?

Arthrosamid is a gel-like injection made from a substance called polyacrylamide hydrogel. When injected into the knee joint, it acts like a cushion, helping to stabilise and protect the joint surfaces. This reduces pain and can improve mobility, offering a possible alternative to more traditional injections or surgery.

Unlike corticosteroid or hyaluronic acid injections, which either reduce inflammation or supplement joint fluid temporarily, Arthrosamid provides a more durable mechanical support inside the joint. This suggests it could offer longer-lasting relief for knee osteoarthritis patients.

Hydrogels like Arthrosamid have been used in medicine for decades. As researchers John R. Clegg and colleagues explain, “Hydrogels have been used in the clinic since the late 1980s with broad applications in drug delivery, cosmetics, tissue regeneration, among many other areas.” Recent advances in how these gels are made and used have led to new treatments entering clinical trials, Arthrosamid included.

In the UK, Arthrosamid has been approved for treating knee osteoarthritis but is still different from the more commonly prescribed injections. Research continues to build the evidence base. A systematic review of clinical studies reported that “Injection of PAAG hydrogel intraarticularly into the knee has been shown to be safe with no long-lasting adverse events reported.” It further notes, “statistically significant data was identified in two studies at both 52 weeks and 13 months. Indicating the efficacy of PAAG hydrogel at one year post injection,” with some benefits lasting up to two years.

Moreover, a recent clinical trial comparing Arthrosamid with hyaluronic acid found that “iPAAG approached superiority to HA across all participants at 52 weeks,” especially in patients under 70 years old, those with a normal BMI, or those with moderate osteoarthritis severity. This suggests Arthrosamid might be particularly effective for certain patient groups.

Throughout this area of emerging treatments, experts such as Professor Paul Lee and the MSK Doctors team provide essential guidance, helping patients understand their options in a safe, professional setting. Growing patient interest in arthrosamid nhs availability reflects hope for easier access to this treatment through the NHS.

Why Isn’t Arthrosamid Routinely Available on the NHS?

The NHS follows a thorough and careful process when considering new treatments for routine use. This involves detailed assessments of how effective and safe a treatment is, alongside analysis of its cost and value for public healthcare budgets.

Currently, Arthrosamid is not routinely available on the NHS. This is primarily because more long-term evidence is needed to confirm how consistently effective it is and whether there are any long-term risks. National health bodies are diligently reviewing emerging research to ensure any decisions are based on solid data.

While the systematic review showed that “this PAAG hydrogel seems to be an efficacious and safe treatment option for knee OA and provides positive results for at least 2 years,” NHS policy-makers require further proof not only of clinical benefit but also of cost-effectiveness before approving widespread funding.

Clinical trials and evaluations continue, with pilot schemes gathering more insight into Arthrosamid’s role in managing knee osteoarthritis. Because of this ongoing evaluation, arthrosamid nhs availability remains limited for now.

This cautious approach by the NHS is designed to protect patients and use resources wisely. Although it might feel frustrating, it helps ensure that treatments offered through the NHS are both safe and provide good value.

Private Access or NHS Access: What Should Patients Know?

Since Arthrosamid is not yet routinely available on the NHS, some patients consider private treatment options. It’s important to understand the differences between private access and NHS availability when making this choice.

Private treatment usually begins with a consultation where a specialist assesses whether Arthrosamid is a suitable option. This involves reviewing your medical history, symptoms, and joint condition. The discussion also covers potential benefits, risks, and importantly, the cost involved.

The expertise of specialists like Professor Paul Lee and the MSK Doctors team is invaluable here. They offer careful assessment and honest advice, helping patients make well-informed decisions based on their individual circumstances.

It’s worth noting that Arthrosamid injections privately can be costly, and prices vary depending on the clinic and treatment plan. Patients should weigh potential benefits against affordability and always seek professional guidance throughout the process.

Making informed choices with expert support ensures patients receive tailored care while managing expectations realistically.

Other Treatment Options and What the Future Might Hold

While waiting for Arthrosamid’s possible NHS approval, there are many other treatments available for knee osteoarthritis. These include corticosteroid injections, hyaluronic acid injections, physiotherapy, pain relief strategies, and for advanced cases, surgery like knee replacement.

The NHS also provides a host of support services such as patient education, rehabilitation, and access to specialist teams to help manage symptoms and improve joint function.

The future of Arthrosamid on the NHS depends on the completion of more clinical trials, the availability of long-term data, and updated national guidelines. Changes in funding priorities and ongoing advocacy by clinicians, including Professor Paul Lee, alongside patient feedback, will play vital roles in shaping access.

MSK Doctors pledge to continue offering responsible, evidence-based care and encourage patients to engage with qualified health professionals when exploring treatment options.

Conclusion

To sum up, Arthrosamid injections are not yet broadly available on the NHS because further evidence and careful evaluation are needed to confirm long-term benefits and cost-effectiveness. This considered approach safeguards patients and ensures public funds are spent wisely.

In the meantime, patients interested in Arthrosamid may choose private treatment, guided by professionals like Professor Paul Lee and MSK Doctors who provide thorough assessments and attentive care. Meanwhile, established NHS treatments and support services continue to play a crucial role in managing knee osteoarthritis.

For personalised medical advice, always consult a qualified healthcare professional.

References

Cole, A., Maulana, R. K., Whitehead, J. P., & Lee, P. Y. F. (2022). A Systematic Review of the Novel Compound Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
Clegg, J. R., Adebowale, K., Zhao, Z., & Mitragotri, S. (2024). Hydrogels in the clinic: An update. Bioengineering & Translational Medicine, 9(6). https://doi.org/10.1002/btm2.10680
Bliddal, H., Beier, J., Hartkopp, A., Conaghan, P. G., & Henriksen, M. (2023). Polyacrylamide hydrogel versus hyaluronic acid in knee osteoarthritis: A subgroup analysis of a randomised study. Orthopaedic Proceedings, 105-B(Supp_13), 81. https://doi.org/10.1302/1358-992x.2023.13.081